Servicio de Farmacia, Hospital Vega Baja de Orihuela, Alicante, España.
Cir Cir. 2024;92(1):28-32. doi: 10.24875/CIRU.22000626.
The aim of this study is to describe the effectiveness and safety of a magistral formulation of diltiazem 2% rectal gel as a treatment for chronic anal fissure.
A retrospective observational study of all patients that began treatment with diltiazem 2% gel during 2019. The primary endpoint of the study was anal fissure healing. We also looked for differences in effectiveness between those initiating treatment and those who had been previously treated, long-term effectiveness through a 2-year follow-up and frequency of adverse effects.
Of the 166 patients included in the study, anal fissure healed in 72.9%. We detected adverse effects in 12 patients, the most common was local irritation. After 2 years of follow-up, 88% of patients did not relapse.
In this study, use of topical diltiazem 2% has been shown to be effective and safe in the treatment of anal fissure and should be considered as the first line of therapy.
本研究旨在描述 2%二氢吡啶直肠凝胶的自制制剂作为慢性肛裂治疗方法的有效性和安全性。
对 2019 年期间开始使用 2%二氢吡啶凝胶治疗的所有患者进行回顾性观察性研究。研究的主要终点是肛裂愈合。我们还比较了开始治疗的患者和既往治疗过的患者之间的疗效差异、2 年随访的长期疗效以及不良反应的频率。
在纳入研究的 166 例患者中,72.9%的患者肛裂愈合。我们发现 12 例患者出现不良反应,最常见的是局部刺激。随访 2 年后,88%的患者未复发。
在这项研究中,外用 2%二氢吡啶已被证明对肛裂的治疗有效且安全,应被视为一线治疗方法。